ClearPoint Neuro (NASDAQ:CLPT) CEO Sells $713,971.74 in Stock

Key Points

• ClearPoint Neuro CEO Joseph Burnett sold 26,463 shares of the company's stock for a total of $713,971.74, reducing his ownership to 217,059 shares.
• ClearPoint Neuro's stock price dipped 0.9% to $26.03, with a current market cap of $740.03 million and a reported earnings per share of ($0.21) for the last quarter.
• Institutional investors hold 30.08% of ClearPoint Neuro's stock, with notable increases in holdings from firms like Osaic Holdings Inc. and Bank of America Corp DE during the second quarter.

ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) CEO Joseph Burnett sold 26,463 shares of ClearPoint Neuro stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $26.98, for a total value of $713,971.74. Following the sale, the chief executive officer owned 217,059 shares in the company, valued at $5,856,251.82. This represents a 10.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ClearPoint Neuro Stock Down 0.9%

Shares of NASDAQ CLPT traded down $0.24 during mid-day trading on Tuesday, hitting $26.03. 766,871 shares of the stock traded hands, compared to its average volume of 459,392. The company has a debt-to-equity ratio of 1.46, a quick ratio of 6.45 and a current ratio of 7.30. ClearPoint Neuro, Inc. has a 52 week low of $9.76 and a 52 week high of $30.10. The company has a market cap of $740.03 million, a price-to-earnings ratio of -32.14 and a beta of 1.19. The stock has a fifty day moving average price of $14.64 and a 200-day moving average price of $13.04.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). ClearPoint Neuro had a negative net margin of 66.15% and a negative return on equity of 94.44%. The firm had revenue of $9.22 million for the quarter, compared to the consensus estimate of $9.20 million. ClearPoint Neuro has set its FY 2025 guidance at EPS. Research analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

Institutional Trading of ClearPoint Neuro

Several large investors have recently modified their holdings of the company. Osaic Holdings Inc. grew its holdings in shares of ClearPoint Neuro by 119.8% in the second quarter. Osaic Holdings Inc. now owns 7,705 shares of the company's stock worth $92,000 after acquiring an additional 4,200 shares during the period. Man Group plc grew its holdings in shares of ClearPoint Neuro by 17.4% in the second quarter. Man Group plc now owns 71,884 shares of the company's stock worth $858,000 after acquiring an additional 10,674 shares during the period. Engineers Gate Manager LP bought a new stake in shares of ClearPoint Neuro in the second quarter worth $219,000. BNP Paribas Financial Markets grew its holdings in shares of ClearPoint Neuro by 2,435.2% in the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company's stock worth $27,000 after acquiring an additional 2,143 shares during the period. Finally, Bank of America Corp DE grew its holdings in shares of ClearPoint Neuro by 315.0% in the second quarter. Bank of America Corp DE now owns 113,698 shares of the company's stock worth $1,358,000 after acquiring an additional 86,304 shares during the period. Institutional investors own 30.08% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Stifel Nicolaus lifted their price target on ClearPoint Neuro from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Wall Street Zen upgraded ClearPoint Neuro from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of ClearPoint Neuro in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, ClearPoint Neuro currently has an average rating of "Moderate Buy" and a consensus price target of $19.67.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.